| pubmed-article:3358806 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3358806 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:3358806 | lifeskim:mentions | umls-concept:C0002144 | lld:lifeskim |
| pubmed-article:3358806 | lifeskim:mentions | umls-concept:C0030086 | lld:lifeskim |
| pubmed-article:3358806 | lifeskim:mentions | umls-concept:C0559546 | lld:lifeskim |
| pubmed-article:3358806 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
| pubmed-article:3358806 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:3358806 | pubmed:dateCreated | 1988-5-13 | lld:pubmed |
| pubmed-article:3358806 | pubmed:abstractText | Six of 9 patients with previously documented adverse reactions to allopurinol exhibited transformation of their peripheral blood lymphocytes when these were exposed in vitro to the allopurinol metabolite, oxypurinol. In 2 of these subjects, intradermal skin challenge was positive at 48 hours with either allopurinol or oxypurinol. The evidence presented suggests that some adverse reactions to allopurinol represent delayed-type hypersensitivity to oxypurinol. | lld:pubmed |
| pubmed-article:3358806 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3358806 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3358806 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3358806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3358806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3358806 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3358806 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3358806 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:3358806 | pubmed:issn | 0004-3591 | lld:pubmed |
| pubmed-article:3358806 | pubmed:author | pubmed-author:EmmersonB TBT | lld:pubmed |
| pubmed-article:3358806 | pubmed:author | pubmed-author:HazeltonR ARA | lld:pubmed |
| pubmed-article:3358806 | pubmed:author | pubmed-author:FrazerI HIH | lld:pubmed |
| pubmed-article:3358806 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3358806 | pubmed:volume | 31 | lld:pubmed |
| pubmed-article:3358806 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3358806 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3358806 | pubmed:pagination | 436-40 | lld:pubmed |
| pubmed-article:3358806 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:meshHeading | pubmed-meshheading:3358806-... | lld:pubmed |
| pubmed-article:3358806 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3358806 | pubmed:articleTitle | Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxypurinol. | lld:pubmed |
| pubmed-article:3358806 | pubmed:affiliation | Department of Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia. | lld:pubmed |
| pubmed-article:3358806 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3358806 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3358806 | lld:pubmed |
